141 related articles for article (PubMed ID: 37887543)
21. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
22. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
Burgener JM; Zou J; Zhao Z; Zheng Y; Shen SY; Huang SH; Keshavarzi S; Xu W; Liu FF; Liu G; Waldron JN; Weinreb I; Spreafico A; Siu LL; de Almeida JR; Goldstein DP; Hoffman MM; De Carvalho DD; Bratman SV
Clin Cancer Res; 2021 Aug; 27(15):4230-4244. PubMed ID: 34158359
[TBL] [Abstract][Full Text] [Related]
23. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
[TBL] [Abstract][Full Text] [Related]
24. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
25. Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.
Zhao S; Cong X; Liu Z
Biomed Res Int; 2021; 2021():8817898. PubMed ID: 33997043
[TBL] [Abstract][Full Text] [Related]
26. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
27. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
28. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
30. The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
Yang X; Xu X; Zhang C; Ji T; Wan T; Liu W
Oral Oncol; 2022 May; 128():105846. PubMed ID: 35358785
[TBL] [Abstract][Full Text] [Related]
31. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
[TBL] [Abstract][Full Text] [Related]
33. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
35. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
36. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
[TBL] [Abstract][Full Text] [Related]
37. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
38. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
39. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
[TBL] [Abstract][Full Text] [Related]
40. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
